Testing effectiveness (Phase 2)UnknownNCT04742400
What this trial is testing
Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis
Who this might be right for
Multiple Sclerosis
National Institute of Neurological Disorders and Stroke (NINDS) 12